Literature DB >> 26629023

Prognostic value of interim (18)F-FDG-PET in diffuse large B cell lymphoma treated with rituximab-based immune-chemotherapy: a systematic review and meta-analysis.

Danxia Zhu1, Xiao-Li Xu2, Cheng Fang1, Mei Ji1, Jun Wu1, Chang-Ping Wu3, Jing-Ting Jiang3.   

Abstract

The prognostic value of an interim fluorine-18-fluorodeoxyglucose positron emission tomography ((18)F-FDG PET) for diffuse large B-cell lymphoma (DLBCL) has been assessed by different groups. However, studies have suggested that the use of rituximab could limit the predictive value of interim (18)F-FDG PET for DLBCL. To clarify the prognostic value of interim (18)F-FDG PET in DLBCL patients treated with rituximab based immunochemotherapy, we searched for relevant studies in PubMed, the Cochrane Library and EMBASE. A random versus fixed effects model was applied according to the heterogeneity. According to the literature search strategies, 11 studies were identified. The pooled HR comparing PFS between patients with positive and negative results was 2.96 (95% CI=2.25-3.89). The patients in interim (18)F-FDG PET negative group had a higher CR rates than that in interim (18)F-FDG PET positive group (RR=5.53, 95% CI=2.59-11.80). Consistent evidence favoring interim (18)F-FDG PET-based treatment assessment should be considered in the management of patients with DLBCL.

Entities:  

Keywords:  18F-FDG PET; DLBCL; meta-analysis; prognosis

Year:  2015        PMID： 26629023      PMCID： PMC4658912     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN： 1940-5901


  33 in total

1.  PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease.

Authors:  Lale Kostakoglu; Morton Coleman; John P Leonard; Ichiei Kuji; Holly Zoe; Stanley J Goldsmith
Journal:  J Nucl Med       Date:  2002-08       Impact factor: 10.057

2.  Limited role of interim PET/CT in patients with diffuse large B-cell lymphoma treated with R-CHOP.

Authors:  Changhoon Yoo; Dae Ho Lee; Jeong Eun Kim; Jungmin Jo; Dok Hyun Yoon; Byeong Seok Sohn; Sang-We Kim; Jung-Shin Lee; Cheolwon Suh
Journal:  Ann Hematol       Date:  2010-12-22       Impact factor: 3.673

3.  Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints.

Authors:  M K Parmar; V Torri; L Stewart
Journal:  Stat Med       Date:  1998-12-30       Impact factor: 2.373

4.  SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma.

Authors:  René-Olivier Casasnovas; Michel Meignan; Alina Berriolo-Riedinger; Stéphane Bardet; Anne Julian; Catherine Thieblemont; Pierre Vera; Serge Bologna; Josette Brière; Jean-Philippe Jais; Corinne Haioun; Bertrand Coiffier; Franck Morschhauser
Journal:  Blood       Date:  2011-04-25       Impact factor: 22.113

5.  Interim FDG PET/CT as a prognostic factor in diffuse large B-cell lymphoma.

Authors:  Silvia Fuertes; Xavier Setoain; Armando Lopez-Guillermo; Josep-Lluis Carrasco; Sonia Rodríguez; Jordina Rovira; Francesca Pons
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-01-23       Impact factor: 9.236

6.  Revised response criteria for malignant lymphoma.

Authors:  Bruce D Cheson; Beate Pfistner; Malik E Juweid; Randy D Gascoyne; Lena Specht; Sandra J Horning; Bertrand Coiffier; Richard I Fisher; Anton Hagenbeek; Emanuele Zucca; Steven T Rosen; Sigrid Stroobants; T Andrew Lister; Richard T Hoppe; Martin Dreyling; Kensei Tobinai; Julie M Vose; Joseph M Connors; Massimo Federico; Volker Diehl
Journal:  J Clin Oncol       Date:  2007-01-22       Impact factor: 44.544

7.  Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.

Authors:  P Feugier; A Van Hoof; C Sebban; P Solal-Celigny; R Bouabdallah; C Fermé; B Christian; E Lepage; H Tilly; F Morschhauser; P Gaulard; G Salles; A Bosly; C Gisselbrecht; F Reyes; B Coiffier
Journal:  J Clin Oncol       Date:  2005-05-02       Impact factor: 44.544

8.  Predictive value of interim ¹⁸F-FDG-PET/CT for event-free survival in patients with diffuse large B-cell lymphoma homogenously treated in a phase II trial with six cycles of R-CHOP-14 plus pegfilgrastim as first-line treatment.

Authors:  Eva González-Barca; Miguel Canales; Montse Cortés; M Jesus Vidal; Antonio Salar; Albert Oriol; Joan Bargay; José L Bello; José J Sánchez; José F Tomás; Eva Donato; Secundino Ferrer; Dolores Caballero
Journal:  Nucl Med Commun       Date:  2013-10       Impact factor: 1.690

9.  Prognostic value of early 18 fluorodeoxyglucose positron emission tomography and gallium-67 scintigraphy in aggressive lymphoma: a prospective comparative study.

Authors:  Christophe Fruchart; Oumedaly Reman; Nolwenn Le Stang; Dada Musafiri; Stéphane Cheze; Margaret Macro; Odile Switsers; Nicolas Aide; Mélanie Liegard; Xavier Levaltier; Anne-Marie Peny; Michel Leporrier; Stéphane Bardet
Journal:  Leuk Lymphoma       Date:  2006-12

10.  Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma.

Authors:  K Spaepen; S Stroobants; P Dupont; P Vandenberghe; J Thomas; T de Groot; J Balzarini; C De Wolf-Peeters; L Mortelmans; G Verhoef
Journal:  Ann Oncol       Date:  2002-09       Impact factor: 32.976
View more
  3 in total

1.  Imaging of primary pediatric lymphoma of bone.

Authors:  Kathryn S Milks; Thomas W McLean; Evelyn Y Anthony
Journal:  Pediatr Radiol       Date:  2016-04-04

2.  Interim and end-of-treatment PET-CT suffers from high false-positive rates in DLBCL: Biopsy is needed prior to treatment decisions.

Authors:  Susanna Tokola; Hanne Kuitunen; Taina Turpeenniemi-Hujanen; Outi Kuittinen
Journal:  Cancer Med       Date:  2021-03-31       Impact factor: 4.452

3.  Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial.

Authors:  Sattva S Neelapu; Michael Dickinson; Javier Munoz; Matthew L Ulrickson; Catherine Thieblemont; Olalekan O Oluwole; Alex F Herrera; Chaitra S Ujjani; Yi Lin; Peter A Riedell; Natasha Kekre; Sven de Vos; Christine Lui; Francesca Milletti; Jinghui Dong; Hairong Xu; Julio C Chavez
Journal:  Nat Med       Date:  2022-03-21       Impact factor: 87.241
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.